1 Meier C, Lamy O, Krieg M. A, Mellinghoff HU, Felder M, Ferrari S, et al. The role of teriparatide in sequential and combination therapy of osteoporosis. Swiss Med Wkly, 2014.144:p.w13952.
2 Meier C, Uebelhart B, Aubry-Rozier B, Birkhaeuser M, Bischoff-Ferrari H, Frey D, et al. Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the Swiss Association against Osteoporosis (SVGO/ASCO). Swiss Med Wkly. 2017;147:w14484.
https://smw.ch/en/article/doi/smw.2017.14484/
3 Baron R, Ferrari S, Russell R. G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–92.
4 Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–9.
5 Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972–80.
6 Meier C, Kraenzlin M, Osteoporose: Therapie-Update, 2. Teil. Medikamente heute und morgen. Swiss Med Forum. 2013;13:835–40.
7 Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16(5):510–6.
8 Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1–34)]. Osteoporos Int. 2004;15(12):992–7.
9 Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. J Clin Endocrinol Metab. 2016:jc20163170.
10 Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. J Bone Miner Res, 2017.
11 Brown JP, Ferrari S, Gilchrist N, Beck Jensen JE, Pannacciulli N. Discontinuation of denosumab and associated vertebral fracture incidence: Analysis from FREEDOM and its extension, in Proceedings of the Annual Meeting of Bone and Mineral Research ASBMR 2016. 2016;Atlanta:sept. 16–19.
12 McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int, 2017;28(5):1723–32.
13 Uebelhart B, Rizzoli R, Ferrari S. Prior exposure to bisphosphonate prevents the rebound of bone turnover markers after denosumab therapy. Osteoporos Int, 2017. in press.
14 Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone. 2017;98:54–8.
15 Recommendations of the Swiss Association against Osteoporosis (SVGO/ASCO). Prevention, Diagnostic and Treatment of Osteoporosis. 2015.